BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up to $4.45

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $4.45, but opened at $5.00. BioCryst Pharmaceuticals shares last traded at $5.35, with a volume of 2,906,898 shares traded.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC restated a "buy" rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $13.83.

BioCryst Pharmaceuticals Stock Up 18.4 %

The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -4.47 and a beta of 1.96. The business has a 50-day moving average of $4.92 and a two-hundred day moving average of $5.46.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.04). The business had revenue of $93.40 million for the quarter, compared to analysts' expectations of $89.19 million. Equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.69 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 15.4% in the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company's stock valued at $106,405,000 after buying an additional 2,371,401 shares during the period. Avoro Capital Advisors LLC boosted its stake in BioCryst Pharmaceuticals by 13.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company's stock worth $78,170,000 after purchasing an additional 1,500,000 shares during the period. Braidwell LP boosted its stake in BioCryst Pharmaceuticals by 6.6% in the 4th quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company's stock worth $34,254,000 after purchasing an additional 355,497 shares during the period. Kynam Capital Management LP boosted its stake in BioCryst Pharmaceuticals by 46.8% in the 4th quarter. Kynam Capital Management LP now owns 4,600,000 shares of the biotechnology company's stock worth $27,554,000 after purchasing an additional 1,466,807 shares during the period. Finally, Deerfield Management Company L.P. Series C boosted its stake in BioCryst Pharmaceuticals by 148.6% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company's stock worth $23,265,000 after purchasing an additional 1,964,000 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.